Antibodies to SARS-CoV-2 and risk of past or future sick leave

The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. We invited all employees (n = 15,300) at work at the Karolinska University Hospital, Stockholm, Sweden to participate in a study examining SARS-Cov-2 antibodies in relation to registered sick lea...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2021-03, Vol.11 (1), p.5160-5160, Article 5160
Main Authors: Dillner, Joakim, Elfström, K. Miriam, Blomqvist, Jonas, Eklund, Carina, Lagheden, Camilla, Nordqvist-Kleppe, Sara, Hellström, Cecilia, Olofsson, Jennie, Andersson, Eni, Jernbom Falk, August, Bergström, Sofia, Hultin, Emilie, Pin, Elisa, Månberg, Anna, Nilsson, Peter, Hedhammar, My, Hober, Sophia, Mattsson, Johan, Mühr, Laila Sara Arroyo, Conneryd Lundgren, Kalle
Format: Article
Language:English
Subjects:
631/326/596/4130
692/308/174
692/420/254
692/699/255
692/700/478/174
692/700/478/2772
Adult
Antibodies
Antibodies, Viral - blood
Antibodies, Viral - immunology
COVID-19
COVID-19 - epidemiology
COVID-19 - immunology
Female
Follow-Up Studies
Humanities and Social Sciences
Humans
Male
Medicin och hälsovetenskap
Middle Aged
multidisciplinary
Multivariate analysis
SARS-CoV-2 - immunology
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
Sick leave
Sick Leave - statistics & numerical data
Sweden - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The extent that antibodies to SARS-CoV-2 may protect against future virus-associated disease is unknown. We invited all employees (n = 15,300) at work at the Karolinska University Hospital, Stockholm, Sweden to participate in a study examining SARS-Cov-2 antibodies in relation to registered sick leave. For consenting 12,928 healthy hospital employees antibodies to SARS-CoV-2 could be determined and compared to participant sick leave records. Subjects with viral serum antibodies were not at excess risk for future sick leave (adjusted odds ratio (OR) controlling for age and sex: 0.85 [95% confidence interval (CI) (0.85 (0.43–1.68)]. By contrast, subjects with antibodies had an excess risk for sick leave in the weeks prior to testing [adjusted OR in multivariate analysis: 3.34 (2.98–3.74)]. Thus, presence of viral antibodies marks past disease and protection against excess risk of future disease. Knowledge of whether exposed subjects have had disease in the past or are at risk for future disease is essential for planning of control measures. Trial registration: First registered on 02/06/20, ClinicalTrials.gov NCT04411576.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-021-84356-w